Watson Agrees to Buy Arrow Group for $1.75 Billion
This article is for subscribers only.
Watson Pharmaceuticals Inc. agreed to buy closely held Arrow Group for $1.75 billion in cash and stock, gaining more than 100 generic medicines.
Watson, the second-largest U.S. maker of generic drugs, agreed to pay $1.05 billion in cash and issue about 16.9 million common shares, as well as $200 million in preferred stock, Corona, California based-Watson said today in a statement.